STOCK TITAN

argenx SE American Depositary Shares - $ARGX STOCK NEWS

Welcome to our dedicated page for argenx SE American Depositary Shares news (Ticker: $ARGX), a resource for investors and traders seeking the latest updates and insights on argenx SE American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect argenx SE American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of argenx SE American Depositary Shares's position in the market.

Rhea-AI Summary
argenx SE announces the approval of VYVDURA for subcutaneous use in Japan, providing more treatment options for adult patients with generalized myasthenia gravis (gMG) who do not respond to other therapies. This approval follows positive results from the Phase 3 ADAPT-SC study, demonstrating comparable efficacy to VYVGART IV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary
argenx SE (ARGX) reported $1.2 billion in preliminary full-year 2023 global net product sales, submitted sBLA to FDA for VYVGART Hytrulo for CIDP with priority review voucher, reported positive data from Phase 2 ARDA study for empasiprubart in MMN, and nominated four new pipeline candidates with IND filings expected by end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
-
Rhea-AI Summary
argenx (ARGX) CEO to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
Rhea-AI Summary
argenx SE (Euronext & Nasdaq: ARGX) announces topline results from the ADDRESS study evaluating efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus, revealing that the study did not meet primary or secondary endpoints. The company will not pursue additional development in pemphigus and plans to prioritize clinical development of efgartigimod in its ongoing severe autoimmune indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.12%
Tags
-
Rhea-AI Summary
argenx SE (ARGX) announces topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo in adults with primary immune thrombocytopenia, which did not meet primary or secondary endpoints, with a favorable safety and tolerability profile. The study enrolled 207 adult patients with chronic and persistent ITP, with 13.7% of treated patients demonstrating a sustained platelet count response compared to 16.2% of placebo patients. The company will host a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.17%
Tags
-
Rhea-AI Summary
argenx SE (ARGX) Receives European Commission Approval for VYVGART® SC Injectable Formulation for gMG Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Rhea-AI Summary
argenx, a global immunology company, will participate in several investor conferences in November, including the Guggenheim 5th Annual Inflammation & Immunology Conference, Truist Securities BioPharma Symposium, and Jefferies London Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
-
Rhea-AI Summary
argenx SE announced 20 presentations of clinical trial and real-world data from studies of VYVGART® and VYVGART Hytrulo® (VYVGART) in neuromuscular autoimmune disease. The data presentations will be featured at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session. Long-term clinical trial and real-world data show consistent and repeatable responses, achievement of minimal symptom expression, and favorable safety profile with VYVGART. Positive results from the ADHERE study of VYVGART Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
-
Rhea-AI Summary
argenx SE announces $329 million in global net product sales for Q3 2023, plans to submit VYVGART Hytrulo sBLA for CIDP by year-end 2023, and publishes results from the ADVANCE-IV study. The company is focused on expanding VYVGART's reach and advancing its FcRn portfolio in autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
Rhea-AI Summary
argenx to host conference call and webcast to discuss Q3 2023 financial results and business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences earnings
argenx SE American Depositary Shares

Nasdaq:ARGX

ARGX Rankings

ARGX Stock Data

23.07B
58.81M
0%
55.84%
2.03%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Breda

About ARGX

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.